The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells.
about
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerUnderstanding and altering cell tropism of vesicular stomatitis virusPermissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activityOncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic virusesBlockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivityMAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirusSuppression of IFN-induced transcription underlies IFN defects generated by activated Ras/MEK in human cancer cells.Gene therapy progress and prospects cancer: oncolytic viruses.Effect of human activated NRAS on replication of delNS1 H5N1 influenza virus in MDCK cells.Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway.An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cellsPosttranslational modification of vesicular stomatitis virus glycoprotein, but not JNK inhibition, is the antiviral mechanism of SP600125IRF1 Downregulation by Ras/MEK Is Independent of Translational Control of IRF1 mRNA.Inhibition of type I interferon-mediated antiviral action in human glioma cells by the IKK inhibitors BMS-345541 and TPCA-1.Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.RNA viruses and the mitogenic Raf/MEK/ERK signal transduction cascade.Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.New perspectives in cancer virotherapy: bringing the immune system into play.The role of signal transducer and activator of transcription-2 in the interferon response.Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer.Targeting Melanoma with Cancer-Killing Viruses.Oncogenic Ras inhibits IRF1 to promote viral oncolysis.Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model.Deregulation of Interferon Signaling in Malignant Cells.Cancer upregulated gene 2, a novel oncogene, confers resistance to oncolytic vesicular stomatitis virus through STAT1-OASL2 signaling.The effect of Zhangfei on the unfolded protein response and growth of cells derived from canine and human osteosarcomas.Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus.Global gene analysis identifying genes commonly regulated by the Ras/Raf/MEK and type I IFN pathways.Activated Ras/MEK inhibits the antiviral response of alpha interferon by reducing STAT2 levels.Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy.DNA-PK inhibition synergizes with oncolytic virus M1 by inhibiting antiviral response and potentiating DNA damage
P2860
Q27021839-799C3212-0878-4DBE-8E23-6AE3669FB288Q27687067-E987A8CA-9140-4363-B5F7-2BAADCCA65FEQ33743847-2D67B3AD-72AC-44E8-91D8-04C706B65A3EQ33924550-60F225FC-5A98-45E9-815E-18F283FA1C96Q34059493-FF795AEE-1759-4005-B918-D60999E68300Q34343725-38F5EEA1-0281-4A28-A08F-051CA6AAB2ABQ34412329-2C5DB70C-EBC6-4E1B-82FF-BED9B3C799AAQ34770611-2C8C9F8E-01A5-4302-97A0-01F3884A3F0FQ35040110-2439F24C-D1EC-400A-BD79-267014924769Q35689692-6188B3C4-CF69-414C-8CE3-9DBE04447644Q35893563-60F787DB-4305-4587-8495-C9AF9F012F44Q35943777-EA90568D-5DE4-4FD3-BE34-7E666341BEB5Q36100040-73A75ED9-4782-4F5C-AB24-A7F8F1DFD231Q36172960-F4BC341C-2663-4DF2-B9D8-763A3D0D4933Q36937117-5ADE048C-3391-4593-B7EB-E195B85ED7A7Q37247071-D11E2EB2-0F72-4997-B780-4262C8B91DE9Q37316872-16A605FE-3E6C-4990-851D-BF916D985AF5Q37564490-903A3457-B0E7-42DD-8258-154498437C22Q37646792-D2EB5F7C-CEBF-46C0-B046-A37A5C702D5EQ37773253-32F03D1B-122A-40BA-9777-9B8F14F8B3A8Q37978889-C1657A3D-B078-4CBB-9810-8FC3BFCC0B5DQ38223419-CB11B854-5143-4618-8498-D0D164E4D64DQ38676416-E42B9893-8F14-40D6-9C22-64F63B2B1056Q38944907-742B511A-9491-470F-AEE5-83123A011B73Q38955561-A85EDE6A-FA70-406E-9726-B9D352BBD282Q38974179-254BA7A4-2B92-4B20-99F3-C7339FBE83D7Q39212798-A078960C-8261-44B7-BBE4-88C2E9C93F5EQ39412639-00E31157-6FED-40CC-8EC7-1B29C78ED84AQ39747959-38755DFF-9EB4-416B-B554-8CDECE4F190AQ40411967-1582F874-78F0-41FF-887E-92C5588637C1Q41359622-AED92D6E-7543-4018-97DA-16F437396FFCQ52688581-377019DC-4782-4D5C-8411-EF7FF470A7B4Q54202657-4836BE66-2D9E-4988-BC79-372BFE27559DQ58600219-70FB5135-F212-4ABA-82D1-60AEDD67ED84
P2860
The RAS/Raf1/MEK/ERK signaling pathway facilitates VSV-mediated oncolysis: implication for the defective interferon response in cancer cells.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The RAS/Raf1/MEK/ERK signaling ...... eron response in cancer cells.
@en
type
label
The RAS/Raf1/MEK/ERK signaling ...... eron response in cancer cells.
@en
prefLabel
The RAS/Raf1/MEK/ERK signaling ...... eron response in cancer cells.
@en
P2093
P356
P1433
P1476
The RAS/Raf1/MEK/ERK signaling ...... eron response in cancer cells.
@en
P2093
Amber A Mael
Josh A Noser
Paola Marcato
Patrick Wk Lee
Ryuta Sakuma
Seiga Ohmine
Yasuhiro Ikeda
P304
P356
10.1038/SJ.MT.6300193
P577
2007-05-15T00:00:00Z